Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Medicine and Dentistry

• Progressive Supranuclear Palsy 100%
• Placebo 100%
• Therapeutic Procedure 69%
• Adverse Event 50%
• Drug 30%
• Tau 20%
• Effect Size 20%
• Rating Scale 20%
• Patient 10%
• Analysis 10%
• Hospital 10%
• Amino Terminal Sequence 10%
• Intention-to-Treat Analysis 10%
• Protein Aggregation 10%
• Neurodegenerative Disorder 10%
• Least Square Analysis 10%
• Interim Analysis 10%
• Passive Immunization 10%
• Death 10%
• Treatment Effect 10%
• Antibodies 10%
• Monoclonal Antibody 10%
• Tau Protein 10%
• Blindness 10%

Nursing and Health Professions

• Placebo 100%
• Progressive Supranuclear Palsy 100%
• Adverse Event 50%
• Drug 30%
• Hospital 20%
• Dose 20%
• Randomization 20%
• Analysis 20%
• Effect Size 20%
• Rating Scale 20%
• Procedures 10%
• Patient 10%
• Medical Specialist 10%
• Blindness 10%
• Intention to Treat Analysis 10%
• Death 10%
• Least Square Analysis 10%
• Passive Immunization 10%
• Disease 10%
• Antibodies 10%
• Monoclonal Antibody 10%
• Tau Protein 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Progressive Supranuclear Palsy 100%
• Adverse Event 50%
• Drug 30%
• Death 10%
• Blindness 10%
• Disease 10%
• Antibodies 10%
• Monoclonal Antibody 10%
• Tau Protein 10%